Navigation Links
Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
Date:3/11/2009

A CCR5 Antagonist That is Dosed Once Daily Could Earn an 18 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed infectious disease specialists identify a therapy's effect on the ability to achieve viral load suppression in treatment-naive patients as the attribute that most influences their prescribing decisions in HIV. Surveyed specialists indicate they are highly satisfied with Gilead/Bristol Myers Squibb's Atripla and Merck's Isentress in this attribute.

The new report entitled HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists finds that a novel drug in the CCR5 antagonist class that is dosed once daily and achieves maximum physician expectations would earn an 18 percent patient share in HIV in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European infectious disease specialists.

In 2008, Decision Resources' proprietary clinical gold standard for HIV was Merck's Isentress/Gilead's Truvada. Based on expert opinion, Isentress/Truvada will retain clinical gold standard status through 2017, owing to its balance of efficacy, novel mechanisms of action and safety. Although some therapies in development for HIV hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed thought leaders believe are inferior when compared with Isentress/Truvada.

"Experts we surveyed rated Isentress plus Truvada as one of the safest antiretroviral regimens available," said Decision Resources Analyst Jose Avalos, Ph.D. "Furthermore, interviewed specialists believe Isentress' novel mechanism of action provides advantages in highly treatment experienced patients."

About the Report

HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. For Primary Care, More Patients Are Seeing Specialists
2. Specialists On Call Earns the Hospital Association of Southern Californias Endorsement
3. Specialists On Call Expands Access to Emergency Neurology On-Call Services in Montana
4. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Virginia
5. Wound Care Certification Course Endorsed by the American College of Certified Wound Specialists
6. Specialists On Call Expands Senior Management & Sales Teams
7. Texas Health Dallas New Intensivist Program Puts Critical-Care Specialists in the ICU - All the Time
8. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Texas
9. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
10. Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions
11. Medical Specialists of the Palm Beaches Selects Allscripts Electronic Health Record to Connect and Automate 85 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised ... five on the list of “ 5 US Cities with the Highest Plastic Rates .” ... and Miami. The results were calculated using a survey by RealSelf and ...
(Date:5/2/2016)... ... May 02, 2016 , ... MedaCheck, a leading medication ... outcomes, has announced its partnership with GrandView Health Services. , With decades of ... counter and prescription drug pharmacy services to thousands of residents. Serving Indiana, Ohio, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which specializes ... today the outcome of their partnership with Yoloha Yoga- producers of high quality cork ... , SUP yoga has seen a dramatic rise in popularity throughout the last few ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept ... Dermatology Surgery & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive ... fat treated and go home or back to work without having to wear recovery ...
(Date:5/2/2016)... Worcester, MA and Shelton, CT (PRWEB) , ... May 02, 2016 ... ... Scott Krug, President and Owner of New England Low Vision and Blindness (NELV&B) ... location will add more flexibility and convenience for people with vision impairments to get ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... NORWALK, Conn. , April 27, 2016 /PRNewswire/ ... availability of its digital health technology platform, which ... services and programs into scalable digital products, Zillion ... mobile engagement and empower consumers to take control ... features face-to-face live video conferencing – including one-to-one, ...
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
Breaking Medicine Technology: